bullish
Opthea (OPT AU): Kicks Off A$80M Capital Raise To Support Phase 3 Trial of Lead Drug Candidate
436 Views25 Aug 2023 23:02
SUMMARY
- Opthea Ltd (OPT AU) is seeking to raise A$80M ($51M) through a combination of private placement and accelerated non-renounceable entitlement offer. The proceeds will fund the clinical development of OPT-302.
- The proceeds of the offer, pending funds from the earlier agreements, along with existing cash balance, are expected to fund the company’s operation through Q3 2024.
- OPT-302 is in two phase 3 trials, which are expected to be fully enrolled by 1H24. In phase 2 trial, OPT-302 has demonstrated superior visual acuity over standard of care.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Opthea (OPT AU): Getting Closer to Commercialization of First Drug; Fund Raising Adds to Confidence03 Sep 2024
- Opthea Ltd (OPT AU): Secured Funds as Lead Eye Drug Candidate Advancing in Phase 3 Trials28 Nov 2022
- Opthea Ltd (OPT AU): Lead Asset for Highly Prevalent Retinal Disease Moving Toward Commercialization04 Aug 2022
x